In the present systematic review and meta-analysis, we found that 6 subtypes of malignant salivary gland tumors had positive HER2 rates higher than 20%, including salivary duct carcinoma in situ, SDC, CXPA, poorly differentiated adenocarcinoma, adenocarcinomas not otherwise specified (NOS), squamous cell carcinomas and mucoepidermoid carcinomas. This evidence concerns the gene ERBB2 and salivary gland cancer.